• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    11/14/25 4:30:04 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care
    Get the next $GUTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Fractyl Health, Inc.

    (Name of Issuer)


    Common Stock, $0.00001 par value per share

    (Title of Class of Securities)


    35168W103

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Maverick Capital, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,248,492.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,248,492.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,248,492.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Maverick Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,248,492.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,248,492.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,248,492.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Lee S. Ainslie III
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,248,492.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,248,492.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,248,492.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Fractyl Health, Inc.
    (b)Address of issuer's principal executive offices:

    3 Van de Graaff Drive, Suite 200, Burlington, MA 01803
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G (the "Schedule 13G") is being filed on behalf of each of the following persons (each, a "Reporting Person"): Maverick Capital, Ltd. ("Maverick"); Maverick Capital Management, LLC ("Maverick Capital Management"); and Lee S. Ainslie III ("Mr. Ainslie"). This Schedule 13G relates to Common Stock (as defined herein) held for the accounts of Maverick's clients.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Maverick and Maverick Capital Management is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.
    (c)Citizenship:

    Maverick is a Texas limited partnership; Maverick Capital Management is a Texas limited liability company; and Mr. Ainslie is a United States citizen.
    (d)Title of class of securities:

    Common Stock, $0.00001 par value per share
    (e)CUSIP No.:

    35168W103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ownership as of September 30, 2025 is incorporated by reference to items (5) - (9) and (11) of the cover pages of the Reporting Persons. The ownership percentages are based on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. Maverick is the investment advisor of (i) Maverick Fund USA, Ltd, a Texas limited partnership, which holds 1,426,999 shares of Common Stock, (ii) Maverick Fund II, Ltd., a Cayman exempt corporation, which holds 894,577 shares of Common Stock, (iii) Maverick Long Enhanced Fund, Ltd, a Cayman exempt corporation, which holds 498,654 shares of Common Stock, (iv) Maverick Long Fund, Ltd., a Cayman exempt corporation, which holds 229,712 shares of Common Stock, (v) Maverick Designated Investments Fund, L.P., a Cayman exempt corporation, which holds 460,330 shares of Common Stock, and (vi) Maverick Growth Fund, L.P., a Delaware limited partnership, which holds 738,220 shares of Common Stock. Maverick is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the shares of Common Stock which are the subject of this filing through the investment discretion it exercises over its clients' accounts. Maverick Capital Management is the General Partner of Maverick. Mr. Ainslie is the manager of Maverick Capital Management and the Managing Partner of Maverick.
    (b)Percent of class:

    Maverick: 3.1% Maverick Capital Management: 3.1% Mr. Ainslie: 3.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Maverick: 0 Maverick Capital Management: 0 Mr. Ainslie: 0

     (ii) Shared power to vote or to direct the vote:

    Maverick: 4,248,492 Maverick Capital Management: 4,248,492 Mr. Ainslie: 4,248,492

     (iii) Sole power to dispose or to direct the disposition of:

    Maverick: 0 Maverick Capital Management: 0 Mr. Ainslie: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Maverick: 4,248,492 Maverick Capital Management: 4,248,492 Mr. Ainslie: 4,248,492

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Maverick Capital, Ltd.
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager
    Date:11/14/2025
     
    Maverick Capital Management, LLC
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:Lee S. Ainslie III, Manager
    Date:11/14/2025
     
    Lee S. Ainslie III
     
    Signature:/s/ Trevor Wiessmann*
    Name/Title:Lee S. Ainslie III
    Date:11/14/2025

    Comments accompanying signature:  *Under Power of Attorney, dated March 15, 2018
    Get the next $GUTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    9/15/2025$9.00Buy
    H.C. Wainwright
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Fractyl Health with a new price target

    H.C. Wainwright initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $9.00

    9/15/25 8:08:19 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

    Ladenburg Thalmann initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $3.60

    8/28/25 8:09:13 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

    BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company's executive leadership team and Board of Directors. Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a str

    1/6/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

    Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D)

    1/5/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/17/26 4:39:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/12/26 4:18:37 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/29/26 8:00:35 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Smith Weber Lara

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:30:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Smith Weber Lara

    3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:15:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, Chief Product Off. Caplan Jay David

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/17/25 6:00:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rajagopalan Harith bought $19,999 worth of shares (10,416 units at $1.92), increasing direct ownership by 2% to 501,745 units (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/8/25 7:05:03 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 7:57:09 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 4:50:44 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Leadership Updates

    Live Leadership Updates

    View All

    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

    BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

    4/2/24 8:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

    LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

    2/20/24 8:38:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Financials

    Live finance-specific insights

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company f

    11/5/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the conference call and presentatio

    8/6/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/14/24 4:30:50 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/13/24 5:17:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

    2/16/24 9:43:25 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care